Demographic Characteristics (Summary)
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total	
	(N=86)	(N=96)	(N=72)	(N=254)	
Age (years)					
n	86	96	72	254	
Mean (SD)	75.2 (8.59)	76.0 (8.11)	73.8 (7.94)	75.1 (8.25)	
Median	76.0	78.0	75.5	77.0	
Min, Max	52, 89	51, 88	56, 88	51, 89	
Age group, n (%)					
18-64	14 (16.3%)	8 (8.3%)	11 (15.3%)	33 (13.0%)	
>64	72 (83.7%)	88 (91.7%)	61 (84.7%)	221 (87.0%)	
Sex, n (%)					
F	53 (61.6%)	55 (57.3%)	35 (48.6%)	143 (56.3%)	
M	33 (38.4%)	41 (42.7%)	37 (51.4%)	111 (43.7%)	
Race, n (%)					
WHITE	78 (90.7%)	90 (93.8%)	62 (86.1%)	230 (90.6%)	
BLACK OR AFRICAN AMERICAN	8 (9.3%)	6 (6.3%)	9 (12.5%)	23 (9.1%)	
AMERICAN INDIAN OR ALASKA NATIVE	0 (0.0%)	0 (0.0%)	1 (1.4%)	1 (0.4%)	
Ethnicity, n (%)					
HISPANIC OR LATINO	3 (3.5%)	6 (6.3%)	3 (4.2%)	12 (4.7%)	
NOT HISPANIC OR LATINO	83 (96.5%)	90 (93.8%)	69 (95.8%)	242 (95.3%)	
Baseline weight (kg)					

Demographic Characteristics (Summary)
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total	
	(N=86)	(N=96)	(N=72)	(N=254)	
n	86	96	72	254	
Mean (SD)	62.76 (12.77)	67.82 (14.49)	69.55 (14.35)	66.60 (14.12)	
Median	60.56	66.68	68.95	66.46	
Min, Max	34.02, 86.18	41.73, 106.14	44.45, 107.96	34.02, 107.96	
Baseline height (cm)					
Mean (SD)	162.6 (11.52)	163.7 (10.30)	165.9 (10.28)	163.9 (10.76)	
Min, Max	137.2, 185.4	135.9, 195.6	146.1, 190.5	135.9, 195.6	
Baseline BMI (kg/m2)					
Mean (SD)	23.63 (3.67)	25.22 (4.39)	25.17 (3.97)	24.67 (4.09)	
Min, Max	15.06, 33.25	15.31, 40.17	13.67, 34.57	13.67, 40.17	
Percentages are based on the number of subjects in the safety analysis set for each treatment group.
Baseline weight, height and body mass index are the ADVS records flagged ABLFL = 'Y'.	
Source: adsl (pharmaverseadam), baseline vital signs from advs. Data cut-off: 2014-07-01. open.csr display t-demographics (in-text variant); generated from the committed ARD.